重组人胰岛素30载  

Thirty years of experience with recombinant human insulin-from familiarity to reliance

作　　者：鲁平[1] 沈丽[2] LU Ping;SHEN Li(Department of Endocrine and Metabolic Diseases, Henan Provincial People ＇s Hospital, Henan, Zhengzhou 450003, Chin)

机构地区：[1]河南省人民医院内分泌代谢科,郑州450003 [2]礼来苏州制药有限公司医学部

出　　处：《中国糖尿病杂志》2018年第1期84-88,共5页Chinese Journal of Diabetes

摘　　要：重组人胰岛素的出现是糖尿病药物治疗领域的一个里程碑,其系列自上世纪80年代开始应用于临床,至今已逾30载,临床实践及众多临床研究验证了其疗效、安全性及效益成本特性。基于循证依据,在众多的糖尿病治疗药物中,人重组胰岛素依然是各大权威糖尿病防治指南推荐的核心降糖药物之一。本文就重组人胰岛素的研发、临床疗效、安全性证据和指南推荐做一综述,为临床个体化胰岛素治疗提供基石。Recombinant human insulin,a milestone of diabetes treatment,has been put into clinical practice for over 30 years since 1980s.Its efficacy,safety and cost-effectiveness have been confirmed by clinical practice and clinical studies.Based on evidences,recombinant human insulin,among many antidiabetic agents,still remains one of the core hypoglycemic drugs recommended by authoritative guidelines for the prevention and treatment of diabetes.This review summarized the development,clinical efficacy,safety profiles and guideline recommendations of recombinant human insulin to lay the cornerstone of individualized insulin therapy.

关 键 词：重组人胰岛素 糖尿病 

分 类 号：R977.15[医药卫生—药品]